Medicamen Organics Limited (NSE:MEDIORG)
India
· Delayed Price · Currency is INR 29.25
-0.80 (-2.66%)
Apr 29, 2026, 3:25 PM IST
Medicamen Organics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 |
| Revenue | 394.3 | 381.88 | 252.72 | 221.47 | 209.75 | 250.47 | Upgrade
|
| Revenue Growth (YoY) | 28.01% | 51.11% | 14.11% | 5.59% | -16.26% | -20.45% | Upgrade
|
| Cost of Revenue | 244.72 | 247.85 | 157.99 | 157.97 | 156.6 | 158.61 | Upgrade
|
| Gross Profit | 149.58 | 134.03 | 94.73 | 63.5 | 53.16 | 91.86 | Upgrade
|
| Selling, General & Admin | 40.22 | 38.71 | 34.27 | 32.63 | 29.18 | 28.2 | Upgrade
|
| Other Operating Expenses | 36.69 | 29.62 | 13.09 | 12.04 | 11.99 | 47.65 | Upgrade
|
| Operating Expenses | 84.77 | 75.69 | 54.55 | 51.79 | 47.98 | 83.69 | Upgrade
|
| Operating Income | 64.81 | 58.33 | 40.18 | 11.71 | 5.18 | 8.17 | Upgrade
|
| Interest Expense | -5.92 | -4.8 | -6.24 | -5.66 | -4.36 | -4.43 | Upgrade
|
| Interest & Investment Income | 0.95 | 0.95 | 0.13 | 0.08 | 0.23 | 0.12 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.16 | 0.16 | 0.02 | -0.14 | -0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.19 | -0.34 | -0.24 | -0.47 | -0.38 | 0.07 | Upgrade
|
| EBT Excluding Unusual Items | 59.81 | 54.3 | 33.86 | 5.53 | 0.67 | 3.93 | Upgrade
|
| Other Unusual Items | 0 | 0 | 10.51 | 8.07 | 1.88 | - | Upgrade
|
| Pretax Income | 59.81 | 54.3 | 44.37 | 13.6 | 2.55 | 3.93 | Upgrade
|
| Income Tax Expense | 14.06 | 13.83 | 18.13 | 3.9 | 1.54 | 1.49 | Upgrade
|
| Net Income | 45.74 | 40.47 | 26.24 | 9.69 | 1.01 | 2.44 | Upgrade
|
| Net Income to Common | 45.74 | 40.47 | 26.24 | 9.69 | 1.01 | 2.44 | Upgrade
|
| Net Income Growth | 79.23% | 54.22% | 170.74% | 855.92% | -58.46% | 138.47% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 11 | 8 | 6 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 11 | 8 | 6 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | 28.87% | 46.18% | 26.05% | - | - | - | Upgrade
|
| EPS (Basic) | 3.88 | 3.67 | 3.47 | 1.62 | 0.17 | 0.41 | Upgrade
|
| EPS (Diluted) | 3.84 | 3.66 | 3.47 | 1.62 | 0.17 | 0.41 | Upgrade
|
| EPS Growth | 39.06% | 5.48% | 114.79% | 855.92% | -58.46% | 139.31% | Upgrade
|
| Free Cash Flow | -25.97 | -69.9 | -40.13 | -8.73 | -5.79 | -12.43 | Upgrade
|
| Free Cash Flow Per Share | -2.18 | -6.32 | -5.31 | -1.46 | -0.96 | -2.07 | Upgrade
|
| Gross Margin | 37.94% | 35.10% | 37.48% | 28.67% | 25.34% | 36.68% | Upgrade
|
| Operating Margin | 16.44% | 15.28% | 15.90% | 5.29% | 2.47% | 3.26% | Upgrade
|
| Profit Margin | 11.60% | 10.60% | 10.38% | 4.38% | 0.48% | 0.97% | Upgrade
|
| Free Cash Flow Margin | -6.59% | -18.30% | -15.88% | -3.94% | -2.76% | -4.96% | Upgrade
|
| EBITDA | 68.6 | 64.31 | 47.38 | 18.83 | 11.98 | 16.02 | Upgrade
|
| EBITDA Margin | 17.40% | 16.84% | 18.75% | 8.50% | 5.71% | 6.40% | Upgrade
|
| D&A For EBITDA | 3.79 | 5.97 | 7.19 | 7.12 | 6.8 | 7.84 | Upgrade
|
| EBIT | 64.81 | 58.33 | 40.18 | 11.71 | 5.18 | 8.17 | Upgrade
|
| EBIT Margin | 16.44% | 15.28% | 15.90% | 5.29% | 2.47% | 3.26% | Upgrade
|
| Effective Tax Rate | 23.51% | 25.47% | 40.85% | 28.71% | 60.27% | 37.91% | Upgrade
|
| Revenue as Reported | 395.4 | 382.83 | 252.9 | 229.62 | 211.87 | 250.66 | Upgrade
|
| Advertising Expenses | - | 1.58 | 0.3 | 0.56 | 0.11 | 0.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.